Author:
Barker Melissa L.,Hathaway Laura B.,Arch Dorinda D.,Westbroek Mark L.,Kushner James P.,Phillips John D.,Franklin Michael R.
Subject
Toxicology,General Medicine
Reference27 articles.
1. Cyp1a2(−/−) null mutant mice develop normally but show deficient drug metabolism;Liang;Proc. Natl. Acad. Sci. U.S.A.,1996
2. Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse;Smith;EHP Toxicogenomics,2003
3. Theophylline pharmacokinetics: comparison of Cyp1a1(−/−) and Cyp1a2(−/−) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice;Derkenne;Pharmacogenet. Genomics,2005
4. Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(−/−) knockout mice;Shertzer;Toxicol. Appl. Pharmacol.,2002
5. Protection of the Cyp1a2(−/−) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin;Smith;Toxicol. Appl. Pharmacol.,2001